Figure 4.

Constructs for testing in vivo activity of aptamers. (A) Complete selected aptamer sequences are shown in the boxes as comparison with the wild-type fdhF construct 60.2, which was used as the basis for all other constructs. The boxed 60.2 sequence was substituted for aptamer sequences shown in the boxes. (B) Construction of “hybrid” aptamers. The boxed 60.2 sequence was substituted for aptamer sequences shown in the boxes. In clones marked by an asterisk, A43 (solid box) was substituted by a cytosine to avoid the UAA stop codon.